GNTA — Genenta Science SpA Income Statement
0.000.00%
Last trade - 00:00- $145.22m
- $130.92m
- 28
- 14
- 52
- 22
Annual income statement for Genenta Science SpA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 5.59 | 5.69 | 11 | 11.7 | 9.76 |
| Operating Profit | -5.59 | -5.69 | -11 | -11.7 | -9.76 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.59 | -5.53 | -8.48 | -11.6 | -8.91 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.59 | -5.53 | -8.48 | -11.6 | -8.91 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.59 | -5.53 | -8.48 | -11.6 | -8.91 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.59 | -5.53 | -8.48 | -11.6 | -8.91 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.309 | -0.304 | -0.465 | -0.639 | -0.488 |